affecting

Cardiol Therapeutics (NASDAQ: CRDL) Advancements in Therapies for Inflammatory Heart Diseases

Source Node:
Time Stamp: October 13, 2023 5:17 AM - Modified On: October 13, 2023 - Published By:
Source Cluster:
Republished By Plato

  In the United States, heart disease accounts for a significant number of deaths every year, with cardiovascular disease being the primary concern. Factors like lifestyle choices and unforeseen circumstances contribute to its prevalence. Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the heart's lining) are two inflammatory heart conditions primarily linked to immunological reactions from viral infections and mRNA vaccines. Though considered rare, awareness of these conditions is growing, especially among younger populations. Recent research in Science Immunology highlighted an increase in cytokine production leading to myocarditis

American Picture House Corporate Update

Source Node:
Time Stamp: September 6, 2023 4:28 PM - Modified On: September 6, 2023 - Published By:
Source Cluster:
Republished By Plato

New York, NY, Raleigh, NC, and Los Angeles, CA.  September 6, 2023 – American Picture House Corporation (OTC: APHP), an entertainment company with a focus on producing feature films, limited series, and entertainment enhancing technologies, today provided a corporate update for shareholders. Industry Strikes American Picture House supports the ideals behind the two current industry strikes -- brought by the Writers Guild of America (“WGA”) and the Screen Actors Guild (“SAG”) -- and joins the many reasonable voices urging for a fair and timely resolution. Update on Feature Films -

Coya Therapeutics Reports Additional Biomarker and Imaging Data Showing Decrease in Neuroinflammation with COYA 301 in Alzheimer’s Disease.

Source Node:
Time Stamp: June 7, 2023 12:22 PM - Modified On: June 7, 2023 - Published By:
Source Cluster:
Republished By Plato

Highlights Coya reports new data illustrating that administration of COYA 301 (low dose Interleukin-2 (IL-2)) in an open- label study in 8 patients with mild to moderate AD (COYA 301 Trial) resulted in a statistically significant reduction in the expression of three well characterized proinflammatory cytokines -- Tumor Necrosis Factor alpha (TNF-α), Interleukin 6 (IL-6), and Interleukin 1- Beta (IL-1β) -- which correlated with lack of cognitive decline of the patients over the course of the study. TNF-α is one of the main inflammatory cytokines involved in initiating and propagating

Paribus: A Regulatory Squeeze.

Source Node:
Time Stamp: February 15, 2023 3:26 AM - Modified On: February 15, 2023 - Published By:
Source Cluster:
Republished By Plato

A Regulatory Squeeze A common narrative you hear in crypto is that regulatory clarity will cause institutional investors to flood into the space. It’s often cited as the trigger for the next bull run. However, each time news of regulations hits the headlines markets plummet, and last week’s settlement between the SEC and Kraken was no exception. While it’s true that forward-thinking regulations will help to remove a lot of uncertainty from the space, it’s doubtful it will cause the next bull run. As we’ve seen from the present market

OKLink Insights: OKLink releases the Global Crypto Market 2022/Q1 Report

Source Node:
Time Stamp: April 14, 2022 10:13 AM - Modified On: April 14, 2022 - Published By:
Source Cluster:
Republished By Plato

-- Monetary policy greatly affecting Cryptocurrency BEIJING, Apr 13, 2022 - (ACN Newswire) - The OKLink team released the Global Crypto Market 2022/Q1 report on April 10, which contains a thorough review on the market performance of various public blockchain as well as in-depth discussion of popular fields and topics in the first quarter. OKLink: Preparing for a prosperous multi-chain era as Ethereum 2.0 is drawing near. [OKLink Global Crypto 2002/Q1 Report] According to OKLink data, MicroStrategy is by far the largest holder of bitcoin amongst overseas listed companies. It